<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Relapse of malignant disease remains the major complication in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC) </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the predictive value of disease-specific markers (<z:chebi fb="4" ids="38624">DSMs</z:chebi>), donor chimerism (DC) analysis of unsorted (UDC) or CD34(+) sorted cells and <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> gene 1 (WT1) expression </plain></SENT>
<SENT sid="2" pm="."><plain>Eighty-eight patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were monitored after allogenic HCT following 2 Gy total-body irradiation with (n=84) or without (n=4) fludarabine 3 × 30 mg/m(2), followed by <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="4" ids="38624">DSMs</z:chebi> were determined by fluorescence in situ hybridization (FISH) and WT1 expression by real-time polymerase chain reaction </plain></SENT>
<SENT sid="4" pm="."><plain>Chimerism analysis was performed on unsorted or CD34(+) sorted cells, by FISH or short tandem repeat polymerase chain reaction </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-one (24%) patients relapsed within 4 months after HCT </plain></SENT>
<SENT sid="6" pm="."><plain>UDC, CD34(+) DC and WT1 expression were each significant predictors of relapse with sensitivities ranging from 53 to 79% and specificities of 82-91% </plain></SENT>
<SENT sid="7" pm="."><plain>Relapse within 28 days was excluded almost entirely on the basis of WT1 expression combined with CD34(+) DC kinetics </plain></SENT>
<SENT sid="8" pm="."><plain>Monitoring of WT1 expression and CD34(+) DC predict relapse of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after RIC-HCT </plain></SENT>
</text></document>